Actively Recruiting
Residual Exacerbations With Mepolizumab
Led by Laval University · Updated on 2025-02-10
60
Participants Needed
1
Research Sites
338 weeks
Total Duration
On this page
Sponsors
L
Laval University
Lead Sponsor
G
GlaxoSmithKline
Collaborating Sponsor
AI-Summary
What this Trial Is About
This will be a two-year prospective study to characterize the nature of the remaining asthma exacerbations in patients treated with mepolizumab. Participants will be assessed every six months from pre- until two years of treatment in addition to whenever they experience an exacerbation of asthma during the study period. During these visits, various clinical, physiological and inflammatory outcomes will be assessed.
CONDITIONS
Official Title
Residual Exacerbations With Mepolizumab
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Proven diagnosis of severe asthma as defined by the Canadian Thoracic Society
- Eligible for mepolizumab treatment
- Able and willing to sign the informed consent form
You will not qualify if you...
- Any respiratory disease apart from asthma
- Confounding comorbidities such as eosinophilic granulomatosis with polyangiitis (EGPA) or hypereosinophilic syndrome
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institut universitaire de cardiologie et de pneumologie de Québec
Québec, Quebec, Canada, G6K 1L8
Actively Recruiting
Research Team
M
Marie-Eve Boulay, MSc
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here